

Anti-ADAR1 Picoband Antibody
Catalog # ABO12661**Specification**

Anti-ADAR1 Picoband Antibody - Product Information

Application	WB, IHC
Primary Accession	P55265
Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Format	Lyophilized

Description

Rabbit IgG polyclonal antibody for Double-stranded RNA-specific adenosine deaminase(ADAR) detection. Tested with WB, IHC-P in Human.

Reconstitution

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

Anti-ADAR1 Picoband Antibody - Additional Information

Gene ID 103

Other Names

Double-stranded RNA-specific adenosine deaminase, DRADA, 3.5.4.37, 136 kDa double-stranded RNA-binding protein, p136, Interferon-inducible protein 4, IFI-4, K88DSRBP, ADAR, ADAR1, DSRAD, G1P1, IFI4

Calculated MW

136066 MW KDa

Application Details

Immunohistochemistry(Paraffin-embedded Section), 0.5-1 µg/ml, Human, By Heat

Western blot, 0.1-0.5 µg/ml, Human

Subcellular Localization

Isoform 1: Cytoplasm. Nucleus. Shuttles between the cytoplasm and nucleus.

Tissue Specificity

Ubiquitously expressed, highest levels were found in brain and lung. Isoform 5 is expressed at higher levels in astrocytomas as compared to normal brain tissue and expression increases strikingly with the severity of the tumor, being higher in the most aggressive tumors. .

Protein Name

Double-stranded RNA-specific adenosine deaminase

Contents

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.

Immunogen

E.coli-derived human ADAR1 recombinant protein (Position: S128-Q346). Human ADAR1 shares 90.2% and 50.7% amino acid (aa) sequence identity with mouse and rat ADAR1, respectively.

Purification

Immunogen affinity purified.

Cross Reactivity

No cross reactivity with other proteins

Storage

At -20°C for one year. After r°Constitution, at 4°C for one month. It°Can also be aliquotted and stored frozen at -20°C for a longer time.Avoid repeated freezing and thawing.

Anti-ADAR1 Picoband Antibody - Protein Information

Name ADAR

Synonyms ADAR1, DSRAD, G1P1, IFI4

Function

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:7972084, PubMed:7565688, PubMed:12618436). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins since the translational machinery read the inosine as a guanosine; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure- dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site- specific editing). Its cellular RNA substrates include: bladder cancer- associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.

Cellular Location

[Isoform 1]: Cytoplasm. Nucleus. Note=Shuttles between the cytoplasm and nucleus (PubMed:7565688, PubMed:24753571). Nuclear import is mediated by TNPO1 (PubMed:24753571).


Tissue Location

Ubiquitously expressed, highest levels were found in brain and lung (PubMed:7972084). Isoform 5 is expressed at higher levels in astrocytomas as compared to normal brain tissue and expression increases strikingly with the severity of the tumor, being higher in the most aggressive tumors.


Anti-ADAR1 Picoband Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-ADAR1 Picoband Antibody - Images

Western blot analysis of ADAR1 expression in HELA whole cell lysates (lane 1), A549 whole cell lysates (lane 2), MCF-7 whole cell lysates (lane 3) and HEPG2 whole cell lysates (lane 4). ADAR1 at 136KD was detected using rabbit anti- ADAR1 Antigen Affinity purified polyclonal antibody (Catalog # ABO12661) at 0.5 µg/mL. The blot was developed using chemiluminescence (ECL) method .



ADAR1 was detected in paraffin-embedded sections of human lung cancer tissues using rabbit anti-ADAR1 Antigen Affinity purified polyclonal antibody (Catalog # ABO12661) at 1 μ g/mL. The immunohistochemical section was developed using SABC method.

Anti-ADAR1 Picoband Antibody - Background

Double-stranded RNA-specific adenosine deaminase, also known as ADAR1, is an enzyme that in humans is encoded by the ADAR gene. It is mapped to 1q21.3. This gene encodes the enzyme responsible for RNA editing by site-specific deamination of adenosines. This enzyme destabilizes double-stranded RNA through conversion of adenosine to inosine. Mutations in this gene have been associated with dyschromatosis symmetrica hereditaria. Alternative splicing results in multiple transcript variants.